Related Experiment Video
Updated: May 31, 2025
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for Treatment
Kangwen Xiao1, Kuangying Yang1, Angela C Hirbe1
1Division of Oncology, Department of Internal Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Abstract:
Malignant peripheral nerve sheath tumors (MPNSTs) are rare but aggressive malignancies with a low 5-year survival rate despite current treatments. MPNSTs frequently harbor mutations in key genes such as NF1, CDKN2A, TP53, and PRC2 components (EED or SUZ12) across different disease stages. With the rapid advancement of high-throughput sequencing technologies, the molecular characteristics driving MPNST development are becoming clearer. This review summarizes recent sequencing studies on peripheral nerve sheath tumors, including plexiform neurofibromas (PNs), atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP), and MPNSTs, highlighting key mutation events in tumor progression from the perspectives of epigenetics, transcriptomics, genomics, proteomics, and metabolomics. We also discuss the therapeutic implications of these genomic findings, focusing on preclinical and clinical trials targeting these alterations. Finally, we conclude that overcoming tumor resistance through combined targeted therapies and personalized treatments based on the molecular characteristics of MPNSTs will be a key direction for future treatment strategies.
Insights
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive cancers with poor survival. Understanding their genetic mutations and molecular drivers is key to developing effective targeted therapies and personalized treatments.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive cancers with a low survival rate.
- Key genes like NF1, CDKN2A, TP53, and PRC2 components are frequently mutated in MPNSTs.
Purpose of the Study:
- To review recent sequencing studies on peripheral nerve sheath tumors (PNs, ANNUBP, MPNSTs).
- To highlight key molecular events driving tumor progression using multi-omics data.
- To discuss therapeutic implications and future treatment strategies for MPNSTs.
Main Methods:
- Comprehensive review of high-throughput sequencing studies.
- Analysis of epigenetic, transcriptomic, genomic, proteomic, and metabolomic data.
- Examination of preclinical and clinical trials targeting MPNST-associated alterations.
Main Results:
- Identified key mutation events in MPNST development and progression.
- Integrated multi-omics data to understand tumor biology.
- Highlighted the potential of targeted therapies based on molecular findings.
Conclusions:
- Molecular insights are crucial for understanding MPNST development.
- Combined targeted therapies and personalized treatments are essential for overcoming tumor resistance.
- Future strategies should focus on molecularly tailored approaches for MPNSTs.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021